Proton pump inhibition for secondary hemochromatosis in hereditary anemia: a phase III placebo‐controlled randomized cross‐over clinical trial. Issue 7 (10th May 2022)

• Record Type: Journal Article
• Authors: van Vuren, Annelies; Kerkhoffs, Jean Louis; Schols, Saskia; Rijneveld, Anita; Nur, Erfan; Peereboom, Dore; Gandon, Yves; Welsing, Paco; van Wijk, Richard; Schutgens, Roger; van Solinge, Wouter; Marx, Joannes; Leiner, Tim; Biemond, Bart; van Beers, Eduard
• Is Part Of: American journal of hematology. Volume 97:Issue 7(2022)
• Page Start: 924
• Page End: 932
• Publication Date: 2022-05-10
• Subjects: Hematology -- Periodicals; 616.15
• DOI: 10.1002/ajh.26581
• Languages: English
• ISSNs: 0361-8609

Abstract

Abstract: Iron overload is a severe general complication of hereditary anemias. Treatment with iron chelators is hampered by important side‐effects, high costs, and the lack of availability in many countries with a high prevalence of hereditary anemias. In this phase III randomized placebo‐controlled trial, we assigned adults with non‐transfusion‐dependent hereditary anemias with mild‐to‐moderate iron overload to receive esomeprazole (at a dose of 40 mg twice daily) or placebo for 12 months in a cross‐over design. The primary end point was change of liver iron content measured by MRI. A total of 30 participants were enrolled in the trial. Treatment with esomeprazole resulted in a statistically significant reduction in liver iron content that was 0.55 mg Fe/g dw larger than after treatment with placebo (95%CI [0.05 to 1.06]; p = 0.03). Median baseline liver iron content at the start of esomeprazole was 4.99 versus 4.49 mg Fe/g dw at start of placebo. Mean delta liver iron content after esomeprazole treatment was −0.57 (SD 1.20) versus −0.11 mg Fe/g dw (SD 0.75) after placebo treatment. Esomeprazole was well tolerated, reported adverse events were mild and none of the patients withdrew from the study due to side effects. In summary, esomeprazole resulted in a significant reduction in liver iron content when compared to placebo in a heterogeneous group of patients with non‐transfusion‐dependent hereditary anemias. From an international perspective this result can have major implications given the fact that proton pump inhibitors may frequently be the only realistic therapy for many patients without access to or not tolerating iron chelators.